Precede Biosciences

Executive Summary

Precede Biosciences is a Boston-based diagnostics company founded in 2021 that aims to revolutionize precision medicine by extracting deep biological insights from a simple blood test. The company's platform is designed to reveal disease-defining biology non-invasively, potentially accelerating drug development and enabling more precise diagnoses. Currently in Phase 1, Precede is leveraging proprietary liquid biopsy technology to address unmet needs in oncology and other therapeutic areas, with the goal of transforming how medicines are developed and how patients are diagnosed. The company has not publicly disclosed funding or valuation, indicating it may be operating under the radar or in early fundraising stages. Its stage and focus suggest a high potential for disruption but also significant execution risk as it moves toward clinical validation.

Upcoming Catalysts (preview)

• Q4 2026Initial clinical data readout from Phase 1 study65% success
• Q3 2026Series A funding announcement70% success
• H1 2027Partnership with a pharmaceutical company for liquid biopsy platform40% success